Skip to main content
. Author manuscript; available in PMC: 2014 Nov 14.
Published in final edited form as: Immunity. 2013 Oct 31;39(5):874–884. doi: 10.1016/j.immuni.2013.08.039

Figure 6. Epirubicin confers protection against severe sepsis in a therapeutic manner.

Figure 6

(a) Survival of C57BL/6 wild-type animals subjected to CLP treated with PBS or epirubicin (same dose as in Figure 1) at indicated times in the absence of meropenem; (b) with administration of meropenem (40μg/g body weight/day) starting at the time of the procedure or (c) with meropenem treatment starting 12 hours after CLP. ns, not significant; *P<0.05; **P<0.01; ***P<0.001 (log-rank (Mantel-Cox)).